Blood-Tinged Tears (Hemolacria): Causes, Pathophysiology, and When to Seek Urgent Medical Care

Hemolacria—often described by the lay term “crying blood”—refers to the appearance of blood or blood-tinged fluid from the eyes. Although the phrase can sound alarming, hemolacria is a descriptive clinical sign rather than a single diagnosis. The key clinical task is to determine the source of blood: is it truly ocular (from conjunctiva/tear-producing structures), systemic, or associated with abnormal bleeding elsewhere (most commonly the nose) that can drain into the nasolacrimal system and then be perceived as coming from the eye. This distinction guides appropriate diagnostic evaluation and urgency.

Pathophysiologically, several mechanisms can produce blood-tinged tears. One group involves local ocular surface bleeding or inflammation. The conjunctiva and periocular tissues are highly vascular; minor trauma, severe conjunctivitis, eyelid margin disease, or neovascularization can lead to bleeding. When tear film carries hemoglobin or mixed exudate, the discharge may appear red or rust-colored.

A second and frequently encountered mechanism involves the nasolacrimal drainage pathway. Tears normally drain from the ocular surface through the puncta into the lacrimal sac and down the nasolacrimal duct to the nasal cavity. If a patient has epistaxis (nosebleeds) or mucosal lesions that bleed, blood may reflux or mix with tear flow, presenting as “blood from the eye.” Posterior epistaxis or heavy anterior bleeding can sometimes make the ocular origin seem more prominent than the nasal source.

Systemic or hematologic causes are also important. Hemostasis disorders—such as thrombocytopenia, hemophilias, von Willebrand disease, liver dysfunction with coagulopathy, or disseminated intravascular coagulation—can increase bleeding susceptibility in mucosal tissues. Medication-related bleeding is another major category: anticoagulants (e.g., warfarin, direct oral anticoagulants), antiplatelet agents (e.g., clopidogrel), and some herbal or drug interactions can predispose to mucosal bleeding, making spontaneous hemolacria more likely after minor irritation.

In some cases, hemolacria can be associated with structural or vascular abnormalities. Local tumors or vascular lesions of the conjunctiva, lacrimal gland, or surrounding tissues may ulcerate and bleed. Less commonly, vascular malformations in the head and neck region can lead to intermittent bleeding that tracks through tear drainage.

Psychological and social factors can amplify distress but do not explain the underlying physiology. When individuals encounter shocking images online, misunderstanding can increase anxiety and delay medical evaluation. Clinically, the focus remains on triage: differentiate benign bleeding due to minor irritation from urgent ocular or systemic pathology.

Clinical evaluation typically begins with history and targeted exam. Clinicians ask about the onset, whether bleeding is unilateral or bilateral, recurrence, duration, pain, photophobia, blurred vision, discharge character, recent trauma, contact lens use, upper respiratory symptoms, and coagulant exposures. Critical red flags include eye pain, reduced visual acuity, severe headache, neurologic symptoms, ongoing heavy bleeding, easy bruising, or bleeding from other sites (gums, urine, stool).

Physical examination should include visual acuity, slit-lamp evaluation when available, assessment of conjunctival injection, presence of active bleeding points, eyelid abnormalities, and examination of the nasal cavity for epistaxis sources. If the nose appears to be bleeding or irritated, confirming nasal origin becomes essential.

Diagnostic workup is tailored to severity and suspicion. Common laboratory tests include a complete blood count with platelet count, coagulation studies (PT/INR, aPTT), and evaluation of liver function when indicated. In patients with concerning ocular findings—such as a visible bleeding lesion—referral to ophthalmology is warranted for imaging and possible biopsy. If systemic bleeding risk is suspected, hematology consultation may be necessary.

Management depends on etiology. If hemolacria results from ocular surface irritation or conjunctivitis, treatment may include lubrication, topical anti-inflammatory therapy, and removal of contributing irritants under clinician guidance. If anticoagulant or antiplatelet therapy is involved, clinicians must balance bleeding risk with thromboembolic risk; medication decisions require prescriber oversight rather than patient self-adjustment. For recurrent epistaxis contributing to tear mixing, addressing nasal causes (e.g., dryness, infection, structural lesions, or hypertension-related bleeding) is central. When a structural ocular lesion is identified, specific interventions such as surgical management, targeted therapy, or hemostatic measures may be required.

Prognosis is generally good when hemolacria is correctly localized and the cause is treated. However, because hemolacria can occasionally indicate systemic coagulopathy or serious ocular disease, it should not be dismissed. Any episode accompanied by pain, visual changes, systemic bleeding signs, or persistent recurrence warrants prompt medical assessment.

Source: @CourtneyMeehan3